Literature DB >> 21704641

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.

Rongrong Jiang1, Satoshi Yamaori, Shuso Takeda, Ikuo Yamamoto, Kazuhito Watanabe.   

Abstract

AIMS: Cannabidiol (CBD), one of the major constituents in marijuana, has been shown to be extensively metabolized by experimental animals and humans. However, human hepatic enzymes responsible for the CBD metabolism remain to be elucidated. In this study, we examined in vitro metabolism of CBD with human liver microsomes (HLMs) to clarify cytochrome P450 (CYP) isoforms involved in the CBD oxidations. MAIN
METHODS: Oxidations of CBD in HLMs and recombinant human CYP enzymes were analyzed by gas chromatography/mass spectrometry. KEY
FINDINGS: CBD was metabolized by pooled HLMs to eight monohydroxylated metabolites (6α-OH-, 6β-OH-, 7-OH-, 1″-OH-, 2″-OH-, 3″-OH-, 4″-OH-, and 5″-OH-CBDs). Among these metabolites, 6α-OH-, 6β-OH-, 7-OH-, and 4″-OH-CBDs were the major ones as estimated from the relative abundance of m/z 478, which was a predominant fragment ion of trimethylsilyl derivatives of the metabolites. Seven of 14 recombinant human CYP enzymes examined (CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) were capable of metabolizing CBD. The correlations between CYP isoform-specific activities and CBD oxidative activities in 16 individual HLMs indicated that 6β-OH- and 4″-OH-CBDs were mainly formed by CYP3A4, which was supported by inhibition studies using ketoconazole and an anti-CYP3A4 antibody. The correlation and inhibition studies also showed that CBD 6α-hydroxylation was mainly catalyzed by CYP3A4 and CYP2C19, whereas CBD 7-hydroxylation was predominantly catalyzed by CYP2C19. SIGNIFICANCE: This study indicated that CBD was extensively metabolized by HLMs. These results suggest that CYP3A4 and CYP2C19 may be major isoforms responsible for 6α-, 6β-, 7-, and/or 4″-hydroxylations of CBD in HLMs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704641     DOI: 10.1016/j.lfs.2011.05.018

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  69 in total

Review 1.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

Review 2.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

3.  Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.

Authors:  William R Arnold; Austin T Weigle; Aditi Das
Journal:  J Inorg Biochem       Date:  2018-04-07       Impact factor: 4.155

4.  Barriers to the wider adoption of medicinal Cannabis.

Authors:  Stephen Ph Alexander
Journal:  Br J Pain       Date:  2020-05-29

5.  Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study.

Authors:  Lanfranco Pellesi; Manuela Licata; Patrizia Verri; Daniele Vandelli; Federica Palazzoli; Filippo Marchesi; Maria Michela Cainazzo; Luigi Alberto Pini; Simona Guerzoni
Journal:  Eur J Clin Pharmacol       Date:  2018-07-06       Impact factor: 2.953

Review 6.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

7.  Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine.

Authors:  Mateus M Bergamaschi; Allan Barnes; Regina H C Queiroz; Yasmin L Hurd; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-15       Impact factor: 4.142

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.

Authors:  William A Kinney; Mark E McDonnell; Hua Marlon Zhong; Chaomin Liu; Lanyi Yang; Wei Ling; Tao Qian; Yu Chen; Zhijie Cai; Dean Petkanas; Douglas E Brenneman
Journal:  ACS Med Chem Lett       Date:  2016-02-10       Impact factor: 4.345

10.  Lifetime Average Cannabis Use in Relation to Hypertriglyceridemic Waist Phenotype in U.S. Adults: A Population-Based Cross-Sectional Study.

Authors:  Gerard Ngueta
Journal:  Cannabis Cannabinoid Res       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.